Evidence map›Paper›PMID 39174806›Full record

ReviewThe AAPS journal2024

Mass Balance in Pharmaceutical Stress Testing: A Review of Principles and Practical Applications.

Stacey Marden, John M Campbell, Neal Adams, Ronan Coelho, Chris Foti, Juçara Ribeiro Franca, Steven Hostyn, Zongyun Huang, Mariah Ultramari, Todd Zelesky and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in The AAPS journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stacey MardenAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, Astrazeneca, Boston, 35 Gatehouse Dr., Waltham, Massachusetts, 02451, USA. stacey.marden@astrazeneca.com.ORCID 0009-0009-3539-6395
John M CampbellAnalytical Development, GSK, 1250 South Collegeville Rd, Mail Stop UP1400, Upper Providence, Pennsylvania, 19426, USA. john.m.campbell@gsk.com.
Neal AdamsScientific and Laboratory Services-Analytical Sciences, Pfizer Inc, Kalamazoo, Michigan, USA.
Ronan CoelhoRegulatory Affairs, Eurofarma Laboratórios SA, Itapevi, São Paulo, Brazil.
Chris FotiAnalytical Development and Operations, Gilead Sciences Inc., Foster City, California, USA.
Juçara Ribeiro FrancaBrazilian Health Regulatory Agency (ANVISA), Brasilia, DF, Brazil.
Steven HostynJanssen Research & Development, LLC, a Johnson & Johnson Company, Predictive Analytics & Stability Sciences Coe, Beerse, Belgium.
Zongyun HuangDrug Product Development, Bristol-Myers Squibb Co., New Brunswick, New Jersey, USA.
Mariah UltramariSpektra Soluções Científico-Regulatórias Ltda, São Paulo, Brazil.
Todd ZeleskyAnalytical Research & Development, Pfizer Inc., Groton, Connecticut, USA.
Steven W BaertschiBaertschi Consulting LLC, Carmel, Indiana, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stress testing (also known as forced degradation) of pharmaceutical drug substances and products is a critical part of the drug development process, providing insight into the degradation pathways of drug substances and drug products. This information is used to support the development of stability-indicating methods (SIMs) capable of detecting pharmaceutically relevant degradation products that might potentially be observed during manufacturing, long-term storage, distribution, and use. Assessing mass balance of stressed samples is a key aspect of developing SIMs and is a regulatory expectation. However, the approaches to measure, calculate, and interpret mass balance can vary among different pharmaceutical companies. Such disparities also pose difficulties for health authorities when reviewing mass balance assessments, which may result in the potential delay of drug application approvals. The authors have gathered input from 10 pharma companies to map out a practical review of science-based approaches and technical details to assess and interpret mass balance results. Key concepts of mass balance are introduced, various mass balance calculations are demonstrated, and recommendations on how to investigate poor mass balance results are presented using real-world case studies. Herein we provide a single source reference on the topic of mass balance in pharmaceutical forced degradation for small molecule drug substances and drug products in support of regulatory submissions with the goal of facilitating a shared understanding among pharmaceutical scientists and health authorities.

Indexed as

Drug StabilityDrug DevelopmentDrug IndustryHumansPharmaceutical PreparationsPharmaceutical PreparationsAnalytical chemistryDegradation productsForced degradationMass balance calculationsStability-indicating methodStress testing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.